General Nieuws Oxurion NV – Publication in ‘Progress in Retinal and Eye Research’ highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD EN april 7, 2021
General Nieuws Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group EN april 6, 2021
General Nieuws Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN januari 20, 2021
